Anti-srIκB Antibody for Mutant-Specific IκB Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of commercially available antibodies that can specifically bind to the super-repressor IκB (srIκB) protein, which is crucial for inhibiting the NF-κB signaling pathway in inflammatory diseases and cancer resistance, due to its high sequence similarity with wild-type IκB, making it difficult to distinguish and bind to the mutated amino acid sites.
Innovation Solution
Development of a novel anti-srIκB antibody with specific binding affinity to srIκB, characterized by heavy and light chain complementarity determining regions (CDRs) that distinguish it from wild-type IκB, along with a method for producing the antibody using nucleic acid encoding and vector technology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibodies are used to detect IκB, then general IκB detection is possible, but specific detection of srIκB is not achieved due to high sequence similarity
Solution Approach 1:
The patent applies local quality by designing antibodies that specifically recognize the mutated amino acid regions (S32A and S36A) in srIκB. The antibody binding sites are localized to epitopes that distinguish srIκB from wild-type IκB, enabling specific detection of the super-repressor form while ignoring the highly similar wild-type sequence.
Solution Approach 2:
The patent utilizes parameter changes by targeting the specific amino acid substitution parameters (Serine to Alanine at positions 32 and 36) that define srIκB. The antibody design exploits these parameter changes in the antigen sequence to achieve discrimination between srIκB and wild-type IκB, transforming the similarity problem into a detectable difference.
2Reliability
If srIκB is used to inhibit NF-κB signaling, then anti-inflammatory effect is achieved, but therapeutic delivery to target cells is limited
Solution Approach 1:
The patent applies the intermediary principle by using exosomes as a mediator to deliver srIκB into target cells. Exosomes serve as natural delivery vehicles that protect srIκB during transport and facilitate its entry into cells, overcoming the limitation of direct srIκB delivery while maintaining its NF-κB inhibition function.
Solution Approach 2:
The patent implements nesting by encapsulating srIκB protein within exosomes. The srIκB is nested inside the exosomal structure, which provides protection and delivery functionality. This nested arrangement allows the therapeutic agent to be delivered efficiently to target cells while maintaining its biological activity.
3Productivity
If exosomes are used to deliver srIκB, then cell delivery efficiency is improved, but production complexity increases
Solution Approach 1:
The patent applies self-service by utilizing the cell's own exosome production machinery to deliver srIκB. Rather than requiring complex external delivery systems, the method employs the natural exosome secretion pathway of cells, allowing the system to self-assemble and self-deliver the therapeutic protein with relatively simple production procedures.
Data Source
AI summary
Provided are a monoclonal or polyclonal antibody against srIκB or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a host cell into which the nucleic acid or the vector is introduced, a method of preparing the antibody or the antigen-binding fragment thereof, and use thereof. The antibody specifically binding to srIκB or the antigen-binding fragment thereof according to the present disclosure is characterized by binding to srIκB, in particular, mutation sites with high affinity, as compared to the wild-type IκB. Accordingly, the antibody specifically binding to srIκB or the antigen-binding fragment thereof according to the present disclosure may be usefully applied to industrial fields where srIκB is used as a target protein.